Product/Service

USP<1062> Tablet Compression Characterization

Medicine-pills-tablets-GettyImages-545993684

Natoli Scientific takes pride in its comprehensive USP<1062> Tablet Compression Characterization services, tailored to address the complexities of tableting in pharmaceutical manufacturing. Staying true to the parameters outlined in the United States Pharmacopeia (USP) Chapter 1062, our approach meticulously evaluates tablet compression behaviors. By thoroughly characterizing the compression profile, we can pinpoint the optimal compression force required to form a cohesive tablet without applying undue stress that could lead to capping — the separation of tablet tops during or after the compression phase.

Natoli Scientific’s preclinical stability studies represent a critical facet of our pharmaceutical testing services, providing essential data on the shelf life and storage conditions of drug candidates. These studies are expertly designed to evaluate physical, chemical, and microbiological stability, ensuring that formulations retain their safety, efficacy, and quality over time. Our state-of-the-art facilities simulate various environmental conditions to scrutinize the integrity of products under stress-testing scenarios. The results gleaned from our stability studies guide the development of robust drug formulations and packaging, aid in regulatory submissions, and lay the groundwork for successful commercialization.

Preliminary Stability Studies

Natoli Scientific offers preclinical preliminary stability studies as a precursor to formal stability testing. These non-GLP (Good Laboratory Practice) studies provide an early glance at the shelf life and resilience of new drug formulations. Tailored to the client’s needs, preliminary stability studies serve as a cost-effective way to identify potential degradation pathways and optimize formulation components before investing in more extensive GLP studies.

Our formulaic approach allows for rapid turnaround times, feeding critical information back into the development pipeline to modify and improve drug candidates during the early stages of drug discovery and development.

Forced Degradation Studies

Forced degradation studies are fundamental in evaluating the stability of pharmaceutical compounds, and Natoli Scientific prides itself on its rigorous approach to these assessments. Our forced degradation protocols are designed to expose drug substances and products to extreme conditions, such as elevated temperatures, humidity, oxidation, photolysis, and hydrolysis. The goal is to understand how the active ingredients and the final products behave under stress, which helps in predicting their degradation products and pathways.

These studies are not only pivotal for determining the shelf life and storage recommendations but are also a key element of the regulatory submission package. Natoli Scientific’s expertise in conducting these studies assures our clients that they will obtain a comprehensive understanding of their product’s stability profile, thereby maximizing its potential for successful market entry and patient safety.

Accelerated Stability Studies

At Natoli Scientific, our accelerated stability studies are a key offering for rapidly assessing pharmaceutical product stability. These studies subject the drug compounds to increased temperature and humidity conditions to accelerate the rate of degradation. This methodology allows us to predict the product’s shelf life and establish expiry dates with a shorter study duration compared to real-time stability testing.

Our precision-controlled environment chambers are calibrated to generate consistent stress conditions, ensuring that clients receive reliable and reproducible data. Leveraging our accelerated stability studies can expedite the development process and support regulatory filings, ultimately bringing effective pharmaceuticals to market more swiftly and safely.

Beyond Use or Expiration Date

To determine the viability of pharmaceutical products over time, Natoli Scientific provides comprehensive services for establishing beyond-use and expiration dates that are compliant with industry standards. By utilizing our two dedicated ICH stability chambers, which are meticulously humidity and temperature controlled, we can accurately simulate long-term storage conditions to assess the degradation of drugs over an extended period. This approach ensures that the potency, purity, and overall quality of the pharmaceutical does not diminish within the set period.

Our rigorous testing procedures, aligned with current regulatory expectations, are key to defining the beyond-use dates for compounded preparations and expiration dates for manufactured drug products. Our commitment to ensuring that these dates are scientifically justified supports pharmacies and manufacturers in protecting patient safety and maintaining compliance with regulatory requirements.

Make Natoli Scientific Your Preclinical Partner Today

At Natoli Scientific, we understand the intricate challenges of drug development and the importance of rigorous preclinical testing. Our comprehensive suite of stability studies, including forced degradation and accelerated stability, are meticulously designed to ensure your pharmaceutical products are safe, effective, and compliant with industry standards.

When you partner with us, you’re not just obtaining quality testing services; you are also leveraging our expertise to streamline your path from the laboratory to the market. Let us help you mitigate risks and achieve your goals with confidence. For pioneering science matched with unparalleled support, call Natoli Scientific at 636-926-8900 today and take the next step towards innovative healthcare solutions that will leave a lasting impact on lives around the globe.

Our skilled analysts employ state-of-the-art technologies to simulate and scrutinize the tablet formation process under a myriad of conditions, which mirrors the variances that occur in a real-world production scenario. This rigorous testing identifies capping and other defects, such as lamination or sticking, ensuring adjustments can be made pre-emptively. The result is a robust formula and tablet design that mitigates the risk of manufacturing errors, underscores patient safety, and upholds the integrity of the final pharmaceutical product. With a focus on delivering insightful data and comprehensive support, Natoli Scientific’s USP<1062> Tablet Compression Characterization is an invaluable step toward achieving seamless, efficient production and market success.

Natoli NP-RD10A and Natoli AIM™ Pro

Quickly & Easily – with only a small amount of material – establish your USP<1062> data

The Natoli NP-RD10A plays a crucial role in our USP<1062> Tablet Compression Characterization procedures. This sophisticated research and development press is engineered to mimic large-scale production environments, providing us with precise data about the compaction characteristics of tablet formulations. With its robust feature set, including the ability to adjust compression parameters and measure detailed force displacement profiles, the NP-RD10A assists our analysts in identifying the optimal compaction parameters that achieve the perfect balance between tablet hardness, friability, and dissolution rates.

The insights yielded by the NP-RD10A and Natoli AIM™ Pro data acquisition and analytical software during this characterization process are vital for our clients, as it ensures that their tablets will not only be produced efficiently at scale but will also meet the stringent quality standards demanded by regulatory authorities and the pharmaceutical industry.

Get Started with our formulation assessment services.

Natoli Engineering Company, Inc.